Skip to main content
Premium Trial:

Request an Annual Quote

Molecular Devices' Shares Tank 17 Percent After Firm Slashes Q3 Revenue Outlook

NEW YORK (GenomeWeb News) – Shares in Molecular Devices were down more than 17 percent, or $3.75, at $18.09 in mid-afternoon trading after the company today slashed its revenue outlook for the third quarter by between 8 percent and 12 percent.
 
As GenomeWeb News reported this morning, Molecular Devices blamed soft sales during the quarter. Molecular Devices said it now expects revenue for the three months ended Sept. 30 to be between $44 million and $46 million.
 
In July the company said it expected to generate between $48 million and $52 million in the period. Third-quarter 2005 revenues were $45.2 million.
 
Molecular Devices in July also cut its full-year 2006 guidance to between $190 million and $198 million from between $198 million and $206 million.
The Scan

Study Reveals Details of SARS-CoV-2 Spread Across Brazil

A genomic analysis in Nature Microbiology explores how SARS-CoV-2 spread into, across, and from Brazil.

New Study Highlights Utility of Mutation Testing in Anaplastic Thyroid Cancer

Genetic mutations in BRAF and RAS are associated with patient outcomes in anaplastic thyroid carcinoma, a new JCO Precision Oncology study reports.

Study Points to Increased Risk of Dangerous Blood Clots in COVID-19 Patients

An analysis in JAMA Internal Medicine finds that even mild COVID-19 increases risk of venous thromboembolism.

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.